How well newer skin treatments work for severe eczema over one year

This is an observational study that tracks how well newer eczema medications—including dupilumab, tralokinumab, upadacitinib, abrocitinib, and baricitinib—work for adults with moderate-to-severe atopic dermatitis. Researchers will follow you for 12 months to understand how long you stay on the medication, how safe it is, and what factors influence whether it continues to work well for you. You don't receive a new drug here; instead, doctors monitor your progress on a medication you're already taking or starting as part of your regular care.

Eczema is a serious, long-lasting skin disease that flares up quickly when treatment stops, making it hard to find the right medication that works long-term. This study helps doctors understand which of the newer treatments are most effective, safest, and most likely to keep working over time—so they can make better choices for future patients.